Compare Ascendis Pharma A/S (ASND) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Trip.com Group Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Trip.com Group Ltd trades at $42.79 (market cap $26.45B). The key difference: Trip.com Group Ltd is the larger of the two by market cap, and Trip.com Group Ltd pays a 0.57% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TCOM | |
|---|---|---|
Market Cap | $17.74B | $26.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $78.96 |
52-Week Low | $163.32 | $39.84 |
Enterprise Value | $18.11B | $19.15B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Trip.com Group (TCOM) trades at $42.80, up 3.31% on the day, with strong fundamentals including a P/E of 6.43 and net income margin of 48.65%. The stock faces technical headwinds with a bearish signal from moving averages and RSI at 82.74 suggesting overbought conditions. Recent Q1 2026 earnings missed expectations at $0.83 vs. $0.85, while revenue guidance for Q2 2026 of 3%-8% growth disappointed investors, triggering an 18% selloff on June 29, 2026.
Despite near-term pressure from regulatory scrutiny and conservative guidance, Trip.com maintains robust profitability and analyst consensus of $56.72 price target with 67% buy ratings. The company's dominant position in China's travel market and strong cash flow generation provide long-term upside potential, though regulatory risks and margin compression remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
